SUZHOU, China – Feb. 11, 2020 — Re-Stem Biotech (Re-Stem or the Company), a biotechnology firm engaged in the research and development of cell-based therapies and products for various indications, including osteoarthritis, stroke, spinal cord injury and cancer, recently provided the banking of immune cells for medical doctors in Hubei, in order to join the fight against the novel coronavirus.
As of 24:00 on February 9, the cumulative number of confirmed cases of the new coronavirus has increased to 35,982, with 6,484 severe cases, 908 deaths, 3,281 cured cases, and 23,589 suspected cases.[1] The First Affiliated Hospital of Gannan Medical University held an expedition ceremony before its medical staff headed towards Wuhan, capital of Central China’s Hubei province, the epicenter of the virus. Re-Stem contributed to their fight against the coronavirus by providing the banking of immune cells for these first-in-line medical staff.
There is currently no vaccine against or specific treatment for coronavirus. A virus is a common microorganism in nature and there is no way to completely kill it. Even if it invades our body, drugs can only inhibit its activity and prevent it from continuing to reproduce. The same is true for the coronavirus. Although it cannot be killed, like other viruses, we can use existing drugs to inhibit its activity and prevent it from multiplying in the human body. The fight against this virus is dependent on the body’s immunity. The immune system is a barrier against bacteria and viruses. It is an important way for the human body to recognize and eliminate foreign invasions and ensure physical health. So far, all treatments have only dealt with the symptoms of the human body after infection. Essentially, they are fighting for the immune system of the human body, and ultimately rely on the immune system to kill the virus.
“Banking of immune cells for the medical staff who went to the frontlines of the epidemic is an attempt to protect the immune system,” commented Benno Jiao, CEO of the Company. “We are proud to support these front-in-line medical staff by cryogenically preserving their immune cells at their most potent state for later use if and when needed. Together we stand to fight against this coronavirus”.
[1] Information from the official website of the National Health and Health Commission. http://www.nhc.gov.cn/
About Re-Stem Biotech
Re-Stem Biotech (Re-Stem) is a biotechnology firm engaged in the research and development of cell-based therapies and products. Backed by state of the art GMP facilities and an international team of world-leading scientists, doctors and management team, Re-Stem currently has a robust technology platform including three profitable therapies on the market and eight other therapies and products in the pipeline. Incorporated and headquartered in 2012 in Suzhou, China, Re-Stem is focused on the large and aging population of China. It also operates clinics and research and development laboratories in Shenzhen, Beijing, Kunming and Ganzhou. For more information visit Re-Stem Biotech website: https://www.restembio.com/
Forward-Looking Statements
Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts and may be forward-looking statements are inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include those regarding our ability to implement objective, plans and strategies for future operations. Forward-looking information may be identified by terms such as “will,” “may,” “expects,” “plans,” “intends,” “estimates,” “potential,” or “continue,” or similar terms or the negative of these terms. Although Re-Stem believes the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that future results, performance or achievements will be obtained. Re-Stem does not have any obligation to update these forward-looking statements other than as required by law.
Contact
Judyanna Yu
COO & CFO, Re-Stem Biotech
judyanna@restembiotech.com